fda compounding glp-1 enforcement news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Escalates Enforcement Against Compounded
Description
Both short- and long-acting GLP-1RAs such as exenatide, lixisenatide and liraglutide were shown to effectively cross the bloodbrain barrier (BBB) [39,40,41]

At regular intervals of 24 hours, the supernatant was collected and subjected to triplicate analysis using the Pierce BCA protein assay kits (ThermoScientific, USA)
It was like being in a tunnel, only able to hear my own magnified voice, she said

Access to Compounded GLP-1s News5Investigates took a hidden camera inside businesses offering GLP-1s to take a look at the market in Colorado Springs
semaglutide 1 mg users at 28 weeks [75]